Table 1.
Patient characteristics of SARS-CoV-2 positive cohort.
| Characteristics | COVID (n = 55) | ||
|---|---|---|---|
| All patients (n = 55) | ICU Admission (n = 15) | Supplemental O2 (n = 25) ψ | |
| Age (years), (median, IQR) | 58 (40; 70) | 59 (50; 69) | 66 (52; 71) |
| Sex (M:F) | 31:24 | 10:5 | 17:8 |
| Ethnicity (no.; %) |
ATSI (1; 1.8%) African (4; 7.3%) Caucasian (31; 56.4%) East Asian (4; 7.3%) Indo-Asian (2; 3.6%) Other (1; 1.8%) Unknown (12; 21.8%) |
African (3; 20%) Caucasian (8; 53.3%) Indo-Asian (1; 6.7%) Other (1; 6.7%) Unknown (2; 13.3%) |
African (2; 8%) Caucasian (17; 68%) East Asian (1; 4%) Indo-Asian (2; 4%) Other (1; 4%) Unknown (3; 12%) |
| Smoking status (no./total no.; %) |
Smoker (4/50; 8%) Ex-smoker (6/50;12%) Non-smoker (40/50; 80%) |
Smoker (1/13; 7.7%) Ex-smoker (1/13; 7.7%) Non-smoker (11/13; 84.6%) |
Smoker (1/21; 4.8%) Ex-smoker (4/21; 19%) Non-smoker (16/21; 76.2%) |
| Comorbidities (no.; %) | |||
| Hypertension | 20; 36.4% | 6; 40% | 14; 56% |
| Cardiac disease | 7; 12.7% | 2; 13.3% | 5; 20% |
| Chronic respiratory disease | 13; 23.6% | 5; 33.3% | 9; 36% |
| Chronic renal or liver disease | 1; 1.8% | 0; 0% | 0; 0% |
| Diabetes | 15; 27.3% | 5; 33.3% | 10; 40% |
| Immunosuppression ♣ | 5; 9.1% | 2; 13.3% | 3; 12% |
| Pregnancy | 1; 1.8% | 0; 0% | 0; 0% |
| ACEI/ARB use | 10; 18.2% | 2; 13.3% | 7; 28% |
| Clinical characteristics | |||
| Charlson comorbidity index ♦ (median, IQR) |
1 (0;3) | 1 (1;2) | 2 (1;3) |
| COVID-MATCH65 Score Φ (median, IQR) |
3.5 (2.5;5) | 4 (3.5;5) | 4.5 (3.5;5) |
| Latency presentation recruitment ▽ (days), (median, IQR) | 7 (5;10) | 7 (5;10) | 7 (5;9) |
| Length of hospital stay (days) (median, IQR) |
6 (3;13) | 17 (9;27) | 13 (6;21) |
| Death (no.; %) | 2; 3.6% | 0; 0% | 2; 8% |
ACEI, angiotensin-converting-enzyme inhibitors; ARB, angiotensin II receptor blockers; ATSI, Aboriginal or Torres Strait Islander; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
♣ The immunosuppression category includes patients that are known for any of the following conditions: transplant recipient, hematological or oncological malignancy (in the last 5 years), corticosteroid use of more than 10 mg prednisolone equivalent per day, connective tissue or autoimmune condition and acquired immunodeficiency syndrome.
Ψ Patients that required supplemental O2 continuously for more than 24 hours during their admission.
♦ The Charlson comorbidity index is age-adjusted.
Φ COVID-MATCH65 Score is a clinical decision rule internally derived that has a high sensitivity (92.6%) and NPV (99.5%) for SARS-CoV-2 and can be used to aid COVID-19 risk assessment and resource allocation for SARS-CoV-2 diagnostics. The resulting score ranges from 1 to 6.5 points with score ≤ 1 representing low risk for a positive test (9).
▽ Time from symptoms presentation and study recruitment (days).